Given that PD−1 effects may not only be immune-mediated but could also exert tumor-intrinsic effects [17], we evaluated the effect of nivolumab (anti-PD−1) in U-251 and U-87 TMZ-r GBM cells. Here, PDCD1 is linked to neoplasm.